Feedback / Questions
Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen
Tezspire: "TEZSPIRE sales increased 46% YoY, driven by volume growth"
(Amgen)
-
Aug 6, 2025 -
Q2 2025 Results
Commercial
•
Asthma • Immunology • Respiratory Diseases
https://investors.amgen.com/static-files/27fcb898-9cee-48db-9684-1da25888c845
Aug 6, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious